CHLOROPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLOROPTIC (CHLOROPTIC).
Chloroptic (chloramphenicol) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
| Metabolism | Primarily hepatic metabolism via glucuronidation; minor metabolism by reduction to aryl amines. |
| Excretion | Primarily renal elimination (70-80% as unchanged drug). Minor biliary/fecal excretion (<10%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function, necessitating frequent dosing (every 4-6 hours) to maintain therapeutic levels. |
| Protein binding | 20-40% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.15-0.25 L/kg, indicating distribution mainly into extracellular fluid. |
| Bioavailability | Topical ophthalmic: low systemic bioavailability (<10%) due to drainage and dilution by tears, with clinical effects largely local. |
| Onset of Action | Ophthalmic: 5-15 minutes after instillation. |
| Duration of Action | Ophthalmic: 4-6 hours, supporting a dosing regimen of every 4-6 hours. |
1 drop (0.5% solution) into the affected eye(s) every 4-6 hours.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | 1 drop (0.5% solution) into the affected eye(s) every 4-6 hours in children ≥2 years. |
| Geriatric use | Same as adult dosing; monitor for local adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHLOROPTIC (CHLOROPTIC).
| Breastfeeding | Chloramphenicol is excreted into breast milk. M/P ratio is approximately 0.5. The American Academy of Pediatrics advises caution due to potential bone marrow suppression and idiopathic aplastic anemia in nursing infants, especially with prolonged use. Topical ophthalmic use likely results in negligible systemic levels, but its use during lactation should be avoided if possible. |
| Teratogenic Risk | Topical ophthalmic chloramphenicol (CHLOROPTIC) has minimal systemic absorption, but due to theoretical risks, use during pregnancy is not recommended unless clearly necessary. First trimester: Potential association with aplastic anemia in offspring (theoretical). Second and third trimesters: Theoretical risk of gray baby syndrome if high systemic levels occur (unlikely with topical use). |
■ FDA Black Box Warning
Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) have been reported after topical ophthalmic use.
| Serious Effects |
Hypersensitivity to chloramphenicol; history of or family history of blood dyscrasias; concomitant use with drugs that suppress bone marrow.
| Precautions | Bone marrow suppression; avoid prolonged use; monitor blood counts if repeated courses; do not use for trivial infections. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of bone marrow suppression (e.g., unexplained bruising, bleeding, infection) in the mother and infant if prolonged therapy is required. Routine complete blood count (CBC) monitoring is advisable. |
| Fertility Effects | There are no known adverse effects of ophthalmic chloramphenicol on human fertility. Animal studies have not shown impaired fertility. |